Board of Directors
![Dr. Anand Tharmaratnam](/sites/default/files/2022-05/anand-tharmaratnam.jpg)
Dr. Anand Tharmaratnam
Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously the president of Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in the anaesthesia.
![Joel Thickins先生](/sites/default/files/2023-11/joel.jpg)
Mr. Joel Thickins
Joel is a Partner at TPG Capital and leads the firm’s investment program in the ANZ region as Head of Australia and New Zealand. Joel has previously served on the board of Inghams Group Limited and Accolade Wines Holding Australia Pty Limited.
Before joining TPG, Joel was a director at CPE Capital (formerly known as CHAMP Private Equity) where he was responsible for the company’s activities in the industrial, agricultural services and consumer markets.
![Dr. Fred Cohen](/sites/default/files/2022-11/fred-cohen.jpg)
Dr. Fred Cohen
Fred Cohen is a Senior Advisor to TPG and was a partner and co-founder of TPG Biotech. Fred has served on the board of several biotech and pharmaceutical organizations including BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and CareDx, Inc. (NASDAQ: CDNA)
![Vincent Wong先生](/sites/default/files/2023-11/vinny.jpg)
Mr. Vincent Wong
Vincent Wong is Partner with TPG Capital and is based in Melbourne, where he works in TPG’s Australian team. Vincent also serves on the board of other TPG investments such as Invocare, iNova, and Funlab. Prior to joining TPG in 2011, Vincent served in the corporate advisory division at Goldman Sachs Australia. Vincent graduated from the University of Melbourne with BCommerce and BLaws (Honors).
![蔡俐女士](/sites/default/files/2022-05/cai-li.jpg)
Ms. Cai Li (蔡俐)
Lydia Cai is a Managing Director with TPG Capital based in Beijing and leads TPG’s healthcare investments in the Greater China area. Prior to joining TPG in 2011, Lydia was an investment associate at HAO Capital, a China-focused early stage private equity fund focusing on growth-stage healthcare investments.
![Dr. John Moller](/sites/default/files/2022-05/john-moller.jpg)
Dr. John Moller
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of Virtus Health Limited. John is a medical doctor by training.
![Ms. Elaine Cheung (張綺玲)](/sites/default/files/2022-05/elaine-cheung.jpg)
Ms. Elaine Cheung (張綺玲)
Ms. Cheung is responsible for providing independent advice to the Board. She chairs the Audit Committee. Ms. Cheung has more than 30 years of corporate experience in the Asia-Pacific region. In January 1990, Ms. Cheung graduated from San Francisco State University with a bachelor of science degree, majoring in business administration.
Senior Management
![Dr. John Moller](/sites/default/files/2022-05/john-moller.jpg)
Dr. John Moller
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of Virtus Health Limited. John is a medical doctor by training.
![Michael stibilj](/sites/default/files/2022-05/michael-stibilj.jpg)
Michael Stibilj
Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.
![Dr. Judith Ng-Cashin](/sites/default/files/2023-09/Judith-Ng-Cashin.jpg)
Dr. Judith Ng-Cashin
Judith joined Novotech in 2023 bringing 20 years of international pharmaceutical, biotech and CRO experience, including multiple senior executive roles, including CMO and CSO roles. Judith, based in the US, is driving Novotech’s global multi-regional later-phase strategy as well as ensuring high quality delivery of medical services to our clients and patients.
![Rob Speedie](/sites/default/files/2022-05/rob-speedie.jpg)
Rob Speedie
Rob was most recently a Managing Director in the TPG Capital Operations Team and lead a number of Strategic Initiatives across TPG’s portfolio, including time as the CPOO at Greencross. Prior to TPG, Rob was a Partner at PwC where he spent a total of 19 years. His roles at PWC included 10 years as a Transaction Services professional and 10 years in audit services across Australia, Asia and US. He worked in a range of industries including the pharmaceutical sector. Rob acted as Investigating Accountant and Signing Partner on multiple IPOs on the ASX, was a member of PwCs technical accounting issues escalation committee and has significant experience in financial due diligence.
![Barry Murphy](/sites/default/files/2022-11/barry-murphy.jpg)
Barry Murphy
Barry joined in July 2014 to lead the growth of Novotech’s Business Development team. Barry started his career as a pharmacist having graduated from the University of Dublin. He has held multiple contract management roles at ICON plc.
![Veronica Holloway](/sites/default/files/2023-05/Veronica-Holloway.jpg)
Veronica Holloway
Veronica joined Novotech in May 2014 to formalise the legal function at Novotech. Prior to Novotech, Veronica held roles as Senior Legal Counsel at EY, Senior Solicitor at Clayton Utz and General Counsel (on secondment) at Novartis Pharmaceuticals Australia Pty Limited. Veronica holds a BA/LLB/LLM.
![Angela Edwardson](/sites/default/files/2022-05/angela-edwardson.jpg)
Angela Edwardson
Angela joined Novotech in November 2015 and is responsible for Novotech's Human Resources operations including strategy, organisational development, remuneration & reward and workplace health and safety. Angela is passionate about delivering Novotech's vision of being the leading CRO in the Asia Pacific region.
![Andy Liu](/sites/default/files/2022-05/andy-liu.jpg)
Andy Liu
Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of across multiple sites in APAC. Andy holds an MBA from the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.
![Iain Gordon](/sites/default/files/2023-10/Iain_gordon.jpg)
Iain Gordon
Iain, with over 20 years of experience in CRO management and corporate development in Europe and North America, joined EastHORN in 2013 as Chief Business Officer. He played a vital role in the company's growth. He has held senior management positions, including European Head and Global VP of Business Development, in the global CRO industry. In 2021, he succeeded Dr. Alan Wood as Executive Chairman, ensuring the company's growth continued apace. After the 2023 merger with Novotech, Iain became Managing Director of Novotech Europe and sits on their Executive Board. Based in the UK, he holds a degree in Cell Biology from the University of Glasgow.
![Rick Farris](/sites/default/files/2023-11/rick.jpg)
Rick Farris
Rick joined Novotech in 2023 with over 22 years of clinical research experience and over 30 years in the life sciences. His clinical research career has been focused wholly on serving the unique needs and challenges of biotech clients. Rick has worked in executive leadership roles in 3 global CROs, leading operations teams and helping organizations build global project support capabilities.